Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2954553 | 0.78 | L3MBTL1 (0.49) | KMT2AMEN1TSHRTP53L3MBTL1 | |
| SCHEMBL4517221 | 0.78 | MAPT (0.45) | KMT2AMEN1TSHRDRD2DRD3 | |
| SCHEMBL5261945 | 0.75 | TSHR (0.59) | KMT2AMEN1TSHRTP53AKR1C3 | |
| SCHEMBL30866830 | 0.75 | TSHR (0.59) | KMT2AMEN1TSHRTP53AKR1C3 | |
| SCHEMBL5829479 | 0.74 | KMT2A (0.78) | KMT2AMEN1TSHRTP53AKR1C3 | |
| SCHEMBL14498366 | 0.74 | L3MBTL1 (0.57) | KMT2AMEN1TSHRL3MBTL1ATM | |
| SCHEMBL12418312 | 0.73 | KMT2A (0.60) | KMT2AMEN1TSHRTP53AKR1C3 | |
| SCHEMBL1134878 | 0.73 | TSHR (0.57) | KMT2AMEN1TSHRTP53AKR1C3 | |
| SCHEMBL692761 | 0.73 | L3MBTL1 (0.60) | KMT2AMEN1TSHRTP53AKR1C3 | |
| SCHEMBL30958764 | 0.73 | TSHR (0.57) | KMT2AMEN1TSHRTP53AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060223829-A1 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-10-05 | — | — | US | claimed |
| US-7759339-B2 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759339-B2 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759339-B2 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-20060223829-A1 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223829-A1 | Hydroxysteroid dehydrogenase inhibitors | HSD17B1, HSD17B3, HSD17B2 | KMT2A 3335/4885MEN1 2689/4885TSHR 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.